Medical Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
In a world where stem cell therapy is often sold as hope, HELENE defines it as proven science backed by real-world results. Based in Tokyo, the pioneering institution is transforming how stem cell therapies are developed and delivered through a fully integrated system that unites science, safety and patient care under one roof. By performing both cell culture and clinical administration on-site, it maintains full control over quality and sterility. This independence fuels continuous innovation. As one of the first medical institutions in Japan certified under the Regenerative Medicine Act, HELENE operates its own ISO-5-grade, GMP-compliant Cell Processing Centers (CPC), where scientists develop and refine proprietary cell technologies. Among these is an animal serum–free mesenchymal stem cell (MSC) culture medium developed entirely in-house, which minimizes allergic and xenogenic risks while meeting PMDA and GMP standards. Every achievement is grounded in evidence. HELENE emphasizes objective validation through imaging assessments, biochemical markers and functional evaluations, ensuring that every therapeutic outcome is supported by measurable scientific data. “Every patient deserves treatment that is innovative and verifiable. Our goal is to combine science, safety and accessibility to deliver real, reliable treatment,” says Dr. Nana Kobayashi, clinic director. A Proven Pathway to Better Patient Outcomes Drawing on more than a decade of clinical experience, a multidisciplinary team spanning neurosurgery, cardiovascular medicine, and internal medicine collaborates to create tailored treatment plans for every patient. Each therapy is designed to restore physiological balance, empowering the body to initiate its own healing process through the immunomodulatory and tissue-regenerative properties of MSCs. Every MSC batch undergoes a rigorous, multi-step verification process before reaching the patient. Using the autoMACS Pro Separator, true MSC populations are selected based on six surface markers, then quantified with the Countess 3 FL automated counter. Viability is confirmed through a proprietary bioactivity assay developed by HELENE’s founder, Dr. Matsuoka and further validated through random third-party testing by Takara Bio. Each sample is also screened for endotoxin, mycoplasma and viral markers including HCV, HBV and HAV, ensuring that the cell bank remains pristine and clinically reliable.
Exercise may be the best medicine, but for many, it’s a hard pill to take. Frailty, limited mobility, old age or chronic conditions can make physical activity challenging or impossible. As a result, the elderly and frail miss out on the benefits of exercise in particular, the activation of the muscle mitochondrial pool that serves to boost systemic metabolism, regulate inflammation and support overall tissue regeneration. MitoCharge by QuantumTX uses a precisely calibrated, low-energy magnetic field to activate the mitochondria without requiring the muscle to move. The technology consists of a magnetic coil-delimited chamber that generates a highly homogeneous magnetic field, ensuring that every muscle within the coil system, no matter how deep, receives uniform and optimal stimulation. The magnetic field is tuned to the specifications that the mitochondria naturally evolved to respond to. The result is highly efficient activation and optimal effects in just 10 minutes of scientifically guided exposure, unlike other methods that require longer sessions. The process is non-invasive and can be performed while fully clothed by simply placing a limb within the coil system. By not causing mechanical stress or muscle damage, the mitochondria are thus able to dedicate their entire energy allotment on producing and releasing restorative factors into the blood stream for the promotion of overall health. Born from nearly two decades of research at ETH Zurich and NUS, MitoCharge is grounded in extensive scientific work that maps how magnetic fields activate mitochondria to mimic the benefits of exercise. The scientific depth gives it an edge over other magnetic systems that lack precise mechanisms or validated outcomes. “In two months with only 80 minutes of total exposure, participants experience meaningful metabolic and functional improvements,” says Prof. Alfredo Franco-Obregón, founding scientist and inventor.
Regenerative Medicine
Kelvin Tan, Visiting Senior Consultant, Tan Tock Seng Hospital
In Vitro Diagnostics
Winny Xie, Molecular Predictive & Diagnostic Lab Head, PT Prodia Widyahusada Tbk
Regenerative Medicine
Christopher Leo, Chairman, Medicine Cluster, Raffles Medical Group
Regenerative Medicine
Colin Baker, Director Medical Imaging and Pathology Contract, Western Health
Regenerative Medicine
Carol Chow, Head of Pharmacy & Research, Gleneagles Hospital Hong Kong
Regenerative Medicine
Natalie Yang, Senior Medical Staff Association Chair, Austin Health
Regenerative Medicine
Janene Lawrence, Clinical Nurse Manager (Medical), Hutt Valley DHB
Regenerative Medicine
Trent Aland, Executive Manager - Clinical Care, Icon Group
Regenerative Medicine
Dr Ana Maria Y. Jimenez, Executive Director of Nursing, Aspen Medical – Fiji
Muscle-metabolic training systems in APAC integrate strength and conditioning, overcoming challenges while creating opportunities through technology, accessibility, and innovation.
APAC regenerative medicine providers are advancing therapies through cell, gene, and tissue engineering, regulatory harmonization, and digital platforms to meet the growing demand for clinical applications.
The New Era of Regeneration and Performance-Focused Care
Next-generation stem cell platforms are refining regenerative care through controlled delivery and measurable biological outcomes. Exosome therapies are extending regenerative signalling into vascular and neurological pathways to target deeper repair.
AI-guided diagnostics are helping clinicians tailor muscle-metabolic training using real-time physiological data. Bioactive rehabilitation devices are accelerating performance recovery by combining mechanical stimulation with cellular support.
This edition of MedTech Outlook APAC brings readers closer to the innovators that are setting new standards for clinical progress.
It features thought leadership articles from Adjunct Assistant Professor Kelvin Tan, Visiting Senior Consultant at Tan Tock Seng Hospital. He explains how orthopaedics in APAC is moving toward technology-enabled joint replacements powered by robotics, computer navigation, 3D printing, AI, digital wearables and AR. Carol Chow, Head of Pharmacy & Research at Gleneagles Hospital Hong Kong examines how hospitals use automated and digital tools to manage medications and how these tools create benefits and new risks.
The edition also features HELENE, a Tokyo-based regenerative medicine institution recognised for developing stem cell therapies through an evidence-driven system.
We hope this edition offers clear insight into the breakthroughs shaping regenerative care and muscle-metabolic training systems across APAC and the leaders driving its progress.
